Cancer vaccines : sixth international symposium / edited by Ralph Steinman, Jacques Banchereau, and Olivera J. Finn

'This volume presents manuscripts stemming from the conference'Sixth International Cancer Vaccine Symposium: Stages of Cancer Vaccine Development,' held at the New York Academy of Sciences Conference Center on Oct. 28-30, 2008.'--P. v

Includes bibliographical references

Some scientific and organizational challenges in cancer immunology -- The human cancer antigen mesothelin is more efficiently presented to the mouse immune system when targeted to the DEC-205/CD205 receptor on dendritic cells -- Brain tumor immunotherapy with type-1 polarizing strategies -- Harnessing human dendritic cell subsets to design novel vaccines -- Dendritic cell-based vaccines for pancreatic cancer and melanoma -- Combining conventional therapies with intratumoral injection of autologous dendritic cells and activated T cells to treat patients with advanced cancers -- Witch hunt against tumor cells enhanced by dendritic cells -- Harnessing CD1D-restricted t cells toward antitumor immunity in humans -- Immunity against cyclin B1 tumor antigen delays development of spontaneous cyclin B1-positive tumors in p53-/- mice -- Targets of protective tumor immunity -- Identification of immunologic biomarkers associated with clinical response after immune-based therapy for cancer -- Harnessing dendritic cells to generate cancer vaccines -- Clinical use of anti-CD25 antibody daclizumab to enhance immune responses to tumor antigen vaccination by targeting regulatory T cells -- Strategies to enhance the therapeutic activity of cancer vaccines: using melanoma as a model -- Hematopoietic stem and progenitor cells and the inflammatory response